메뉴 건너뛰기




Volumn 38, Issue 10, 2011, Pages 1788-1797

Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y/ 177 Lu-DOTATATE: Which is a better therapy option?

Author keywords

Neuroendocrine tumours; Peptide receptor radionuclide therapy; Somatostatin receptor

Indexed keywords

AMINO ACID; LUTETIUM 177; YTTRIUM 90;

EID: 80455164737     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1833-x     Document Type: Article
Times cited : (194)

References (26)
  • 1
    • 69749117558 scopus 로고    scopus 로고
    • ENETS consensus guidelines for standards of care in neuroendocrine tumors: Chemotherapy in patients with neuroendocrine tumors
    • Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, et al. ENETS Consensus Guidelines for Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009;90:214-9.
    • (2009) Neuroendocrinology , vol.90 , pp. 214-219
    • Eriksson, B.1    Annibale, B.2    Bajetta, E.3    Mitry, E.4    Pavel, M.5    Platania, M.6
  • 3
    • 0024573688 scopus 로고
    • Use of somatostatin analog in management of carcinoid syndrome
    • Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989;34 Suppl 3:14S-27.
    • (1989) Dig Dis Sci , vol.34 , Issue.3 SUPPL.
    • Vinik, A.1    Moattari, A.R.2
  • 4
    • 70350442637 scopus 로고    scopus 로고
    • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients wit metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
    • Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients wit metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
    • (2009) J Clin Oncol , vol.27 , pp. 4656-4663
    • Rinke, A.1    Muller, H.-H.2    Schade-Brittinger, C.3
  • 6
    • 0034742565 scopus 로고    scopus 로고
    • 90 Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
    • DOI 10.1023/A:1011160913619
    • Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5. (Pubitemid 32725766)
    • (2001) Annals of Oncology , vol.12 , Issue.7 , pp. 941-945
    • Waldherr, C.1    Pless, M.2    Maecke, H.R.3    Haldemann, A.4    Mueller-Brand, J.5
  • 7
    • 0036976703 scopus 로고    scopus 로고
    • 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies
    • Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393-8.
    • (2002) Biopolymers , vol.66 , pp. 393-398
    • Paganelli, G.1    Bodei, L.2    Junak, D.H.3    Rocca, P.4    Papi, S.5    Sierra, M.L.6
  • 12
    • 0037855590 scopus 로고    scopus 로고
    • Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labeled analogs only
    • de Jong M, Bernard HF, Breeman WA, et al. Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labeled analogs only. J Nucl Med 2002;43:123P-4.
    • (2002) J Nucl Med , vol.43
    • De Jong, M.1    Bernard, H.F.2    Breeman, W.A.3
  • 13
    • 14844350129 scopus 로고    scopus 로고
    • Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs
    • de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S-7.
    • (2005) J Nucl Med , vol.46 , Issue.1 SUPPL.
    • De Jong, M.1    Breeman, W.A.2    Valkema, R.3    Bernard, B.F.4    Krenning, E.P.5
  • 15
    • 27744479810 scopus 로고    scopus 로고
    • 0 ]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization?
    • Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0, Tyr3, Thr8]octreotide and [111In-DTPA0] octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561-9. (Pubitemid 46173268)
    • (2005) Journal of Nuclear Medicine , vol.46 , Issue.9 , pp. 1561-1569
    • Storch, D.1    Behe, M.2    Walter, M.A.3    Chen, J.4    Powell, P.5    Mikolajczak, R.6    Macke, H.R.7
  • 16
    • 0031911476 scopus 로고    scopus 로고
    • Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
    • DOI 10.1007/s002590050216
    • Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12. (Pubitemid 28130048)
    • (1998) European Journal of Nuclear Medicine , vol.25 , Issue.2 , pp. 201-212
    • Behr, T.M.1    Goldenberg, D.M.2    Becker, W.3
  • 19
    • 0034789262 scopus 로고    scopus 로고
    • Low-energy electron emitters for targeted radiotherapy of small tumours
    • DOI 10.1080/028418601750444141
    • Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602-8. (Pubitemid 32912438)
    • (2001) Acta Oncologica , vol.40 , Issue.5 , pp. 602-608
    • Bernhardt, P.1    Forssell-Aronsson, E.2    Jacobsson, L.3    Skarnemark, G.4
  • 21
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 22
    • 77956888457 scopus 로고
    • Partial residuals for the proportional hazards regression model
    • Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
    • (1982) Biometrika , vol.69 , pp. 239-241
    • Schoenfeld, D.1
  • 25
    • 14844340284 scopus 로고    scopus 로고
    • Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs
    • Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S-6.
    • (2005) J Nucl Med , vol.46 , Issue.1 SUPPL.
    • Kwekkeboom, D.J.1    Mueller-Brand, J.2    Paganelli, G.3    Anthony, L.B.4    Pauwels, S.5    Kvols, L.K.6
  • 26
    • 43749091955 scopus 로고    scopus 로고
    • Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival
    • Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
    • (2008) J Clin Oncol , vol.26 , pp. 2124-2130
    • Kwekkeboom, D.J.1    De Herder, W.W.2    Kam, B.L.3    Van Eijck, C.H.4    Van Essen, M.5    Kooij, P.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.